ADAR1 Inhibits HBV DNA Replication via Regulating miR-122-5p in Palmitic Acid Treated HepG2.2.15 Cells

References

• Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864. doi:10.1053/j.gastro.2020.01.052
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi:10.1016/S2468-1253(19)30039-1
   PubMed Web of Science ®Google Scholar
• Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi:10.1016/S2468-1253(18)30056-6
   PubMed Web of Science ®Google Scholar
• Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1100–1109. doi:10.1111/apt.16595
   PubMed Web of Science ®Google Scholar
• Butler EK, Gersch J, McNamara A, et al. Hepatitis B virus serum DNA andRNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology. 2018;68(6):2106–2117. doi:10.1002/hep.30082
   PubMed Web of Science ®Google Scholar
• Joo E-J, Chang Y, Yeom J-S, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65(3):828–835. doi:10.1002/hep.28917
   PubMed Web of Science ®Google Scholar
• Peleg N, Issachar A, Sneh Arbib O, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 2019;1(1):9–16. doi:10.1016/j.jhepr.2019.02.002
   PubMedGoogle Scholar
• Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361–1367. doi:10.1111/j.1440-1746.2011.06801.x
   PubMed Web of Science ®Google Scholar
• Karacaer Z, Okur G, Cermik H, Altun D. Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B?. Postgrad Med. 2016;128(7):697–700. doi:10.1080/00325481.2016.1221733
   PubMed Web of Science ®Google Scholar
• Li J, Le AK, Chaung KT, et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int. 2020;40(5):1052–1061. doi:10.1111/liv.14415
   Web of Science ®Google Scholar
• Ceylan B, Arslan F, Batirel A, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol. 2016;27(1):42–46. doi:10.5152/tjg.2015.150348
   PubMed Web of Science ®Google Scholar
• Li J, Yang HI, Yeh ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis. 2021;224(2):294–302. doi:10.1093/infdis/jiaa739
   PubMed Web of Science ®Google Scholar
• Chen Y, Fan C, Chen Y, et al. Effect of hepatic steatosis on the progression of chronic hepatitis B: a prospective cohort and in vitro study. Oncotarget. 2017;8(35):58601–58610. doi:10.18632/oncotarget.17380
   PubMedGoogle Scholar
• Tomar A, Bhardwaj A, Choudhary A, Bhattacharyya D. Association of obstructive sleep apnea with nocturnal hypoxemia in metabolic-associated fatty liver disease patients: a cross-sectional analysis of record-based data. J Family Med Prim Care. 2021;10(8):3105–3110. doi:10.4103/jfmpc.jfmpc_412_21
   PubMedGoogle Scholar
• Pais R, Rusu E, Zilisteanu D, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. Eur J Intern Med. 2015;26(1):30–36. doi:10.1016/j.ejim.2014.12.001
   Web of Science ®Google Scholar
• Pujantell M, Franco S, Galvan-Femenia I, et al. ADAR1 affects HCV infection by modulating innate immune response. Antiviral Res. 2018;156:116–127. doi:10.1016/j.antiviral.2018.05.012
   Web of Science ®Google Scholar
• Li T, Yang X, Li W, et al. ADAR1 stimulation by ifn-alpha downregulates the expression of MAVS via RNA editing to regulate the Anti-HBV response. Mol Ther. 2021;29(3):1335–1348. doi:10.1016/j.ymthe.2020.11.031
   Web of Science ®Google Scholar
• Wang L, Sun Y, Song X, et al. Hepatitis B virus evades immune recognition via RNA adenosine deaminase ADAR1-mediated viral RNA editing in hepatocytes. Cell Mol Immunol. 2021;18(8):1871–1882. doi:10.1038/s41423-021-00729-1
   Web of Science ®Google Scholar
• van der Kwast R, van Ingen E, Parma L, Peters HAB, Quax PHA, Nossent AY. Adenosine-to-inosine editing of MicroRNA-487b alters target gene selection after ischemia and promotes neovascularization. Circ Res. 2018;122(3):444–456. doi:10.1161/CIRCRESAHA.117.312345
   PubMed Web of Science ®Google Scholar
• Qiu L, Fan H, Jin W, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun. 2010;398(4):771–777. doi:10.1016/j.bbrc.2010.07.021
   PubMed Web of Science ®Google Scholar
• Wang S, Qiu L, Yan X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology. 2012;55(3):730–741. doi:10.1002/hep.24809
   PubMed Web of Science ®Google Scholar
• Hu D, Wang H, Wang H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12(5):438–446. doi:10.1007/s12072-018-9877-7
   PubMed Web of Science ®Google Scholar
• Zhang Z, Pan Q, Duan XY, et al. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol. 2012;27(12):1858–1864. doi:10.1111/j.1440-1746.2012.07268.x
   Web of Science ®Google Scholar
• Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF. The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. Cell Mol Life Sci. 2018;75(21):3895–3905. doi:10.1007/s00018-018-2892-y
   Web of Science ®Google Scholar
• Ramiere C, Scholtes C, Diaz O, et al. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha. J Virol. 2008;82(21):10832–10840. doi:10.1128/JVI.00883-08
   PubMed Web of Science ®Google Scholar
• Zhao K, Liu S, Chen Y, et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018;7(1):186. doi:10.1038/s41426-018-0189-8
   Web of Science ®Google Scholar
• Wang QX, Xue J, Shi MJ, et al. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective cohort study. Diabetes Metab Syndr Obes. 2022;15:2311–2322. doi:10.2147/DMSO.S369824
   PubMed Web of Science ®Google Scholar
• Fritzell K, Xu LD, Lagergren J, Ohman M. ADARs and editing: the role of A-to-I RNA modification in cancer progression. Semin Cell Dev Biol. 2018;79:123–130. doi:10.1016/j.semcdb.2017.11.018
   PubMed Web of Science ®Google Scholar
• Chan TH, Lin CH, Qi L, et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014;63(5):832–843. doi:10.1136/gutjnl-2012-304037
   PubMed Web of Science ®Google Scholar
• Wang Q, Li X, Qi R, Billiar T, Editing RNA. ADAR1, and the innate immune response. Genes. 2017;8(1):41. doi:10.3390/genes8010041
   Web of Science ®Google Scholar
• Liu G, Ma X, Wang Z, et al. Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing. J Biol Chem. 2019;294(38):14043–14054 doi:10.1074/jbc.RA119.007970
   Web of Science ®Google Scholar
• Ben-Shoshan SO, Kagan P, Sultan M, et al. ADAR1 deletion induces NFkappaB and interferon signaling dependent liver inflammation and fibrosis. RNA Biol. 2017;14(5):587–602. doi:10.1080/15476286.2016.1203501
   PubMed Web of Science ®Google Scholar
• Anadon C, Guil S, Simo-Riudalbas L, et al. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene. 2016;35(33):4422. doi:10.1038/onc.2016.27
   PubMed Web of Science ®Google Scholar
• Chan TH, Qamra A, Tan KT, et al. ADAR-Mediated RNA editing predicts progression and prognosis of gastric cancer. Gastroenterology. 2016;151(4):637–50 e10. doi:10.1053/j.gastro.2016.06.043
   PubMed Web of Science ®Google Scholar
• Wang H, Wang G, Zhang L, et al. ADAR1 suppresses the activation of cytosolic RNA-sensing signaling pathways to protect the liver from ischemia/reperfusion injury. Sci Rep. 2016;6:20248. doi:10.1038/srep20248
   Web of Science ®Google Scholar
• Michailidis E, Pabon J, Xiang K, et al. A robust cell culture system supporting the complete life cycle of hepatitis B virus. Sci Rep. 2017;7(1):16616. doi:10.1038/s41598-017-16882-5
   PubMed Web of Science ®Google Scholar